We're looking for help to shape our input into the National Institute for Health and Care Excellence’s (NICE) appraisal into trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer. Enhertu has been available for this group of patients through the cancer drugs fund since 2023, allowing NICE and the pharmaceutical companies to collect more data on its effectiveness. The appraisal will consider whether it should be made routinely available on the NHS. This decision will affect a different group of patients to the ones we campaigned for in our #EnhertuEmergency campaign. We’re interested to hear from anyone with HER2+ secondary breast cancer who has received Enhertu. By sharing your experience of the treatment you’ll help to shape our input into NICE’s appraisal. If you’d be happy to share your experience, please email policy@breastcancernow.org by 5pm Friday 11 April.
